RxDoctor Payments Data

William Kraklow, MD

Nephrology · Milwaukee, WINPI 1184616187

Payments from drug & device makers

$161in general payments, 2019–2025

Across 8 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$96
  • Fresenius USA Marketing, Inc.$34
  • Akebia Therapeutics Inc$25
  • Travere Therapeutics, Inc.$7

What the payments were for

  • Food & beverage$3421%
  • Education$12779%

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$161 in reported general payments places this provider in the 35th percentile of 173 nephrology providers in Wisconsin.

See all nephrology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$328,929
Medicare patients
705
Services billed
2,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide41$96,924
JardianceEmpagliflozin35$47,956
AuryxiaFerric Citrate19$36,695
LokelmaSodium Zirconium Cyclosilicate15$16,923
Sevelamer Carbonate150$16,887
Potassium Chloride50$1,571
Hydralazine Hcl97$1,556
Midodrine Hcl29$1,520
Furosemide238$1,177
Tamsulosin Hcl24$940
Metolazone45$812
Losartan Potassium106$619
Oxybutynin Chloride ErOxybutynin Chloride34$606
Bumetanide14$570
Amlodipine Besylate85$547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$34$96,92441 claims
Akebia Therapeutics IncAuryxia$25$36,69519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 173 nephrology providers in Wisconsin.

Other nephrology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →